Mark Foletta
Director/Board Member at DEXCOM, INC.
Net worth: 9 M $ as of 29/04/2024
Mark Foletta active positions
Companies | Position | Start | End |
---|---|---|---|
AMN HEALTHCARE SERVICES, INC. | Director/Board Member | 11/12/2012 | - |
Independent Dir/Board Member | 19/05/2013 | - | |
DEXCOM, INC. | Director/Board Member | 18/11/2014 | - |
Independent Dir/Board Member | 18/11/2014 | - | |
ENANTA PHARMACEUTICALS, INC. | Director/Board Member | 28/06/2020 | - |
Independent Dir/Board Member | 28/06/2020 | - | |
Corporate Directors Forum
Corporate Directors Forum Miscellaneous Commercial ServicesCommercial Services Corporate Directors Forum operates as a forum for corporate directors. The non-profit company is based in La Jolla, CA. | Corporate Officer/Principal | - | - |
The Financial Executives Institute | Corporate Officer/Principal | - | - |
Career history of Mark Foletta
Former positions of Mark Foletta
Companies | Position | Start | End |
---|---|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Director/Board Member | 18/12/2013 | 31/08/2022 |
FORTE BIOSCIENCES, INC. | Director of Finance/CFO | 31/01/2017 | 14/06/2020 |
REGULUS THERAPEUTICS INC. | Director/Board Member | 31/01/2013 | 30/05/2018 |
Independent Dir/Board Member | 30/06/2014 | 30/05/2018 | |
BIOCEPT, INC. | Comptroller/Controller/Auditor | 20/08/2015 | 26/07/2016 |
Director of Finance/CFO | 20/08/2015 | 26/07/2016 | |
░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Mark Foletta
University of California, Santa Barbara | Undergraduate Degree |
Statistics
International
United States | 17 |
Operational
Director/Board Member | 8 |
Independent Dir/Board Member | 6 |
Director of Finance/CFO | 5 |
Sectoral
Health Technology | 10 |
Commercial Services | 6 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 5 |
---|---|
REGULUS THERAPEUTICS INC. | Health Technology |
AMN HEALTHCARE SERVICES, INC. | Commercial Services |
DEXCOM, INC. | Health Technology |
BIOCEPT, INC. | Health Technology |
ENANTA PHARMACEUTICALS, INC. | Health Technology |
Private companies | 10 |
---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
The Financial Executives Institute | |
Intermark, Inc. | Commercial Services |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Health Technology |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
Islet Sciences, Inc.
Islet Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Islet Sciences, Inc. is a biotechnology company, which engaged in the research, development, and commercialization of new medicines and technologies for the treatment of metabolic diseases. Its product portfolio included small molecule therapeutics, islet cell transplantation, and a molecular diagnostic to detect the onset of diabetes. The company was founded on September 14, 1994 and is headquartered in Yorba Linda, CA. | Commercial Services |
Ambit Biosciences Corp.
Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
Corporate Directors Forum
Corporate Directors Forum Miscellaneous Commercial ServicesCommercial Services Corporate Directors Forum operates as a forum for corporate directors. The non-profit company is based in La Jolla, CA. | Commercial Services |
Tocagen, Inc.
Tocagen, Inc. BiotechnologyHealth Technology Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Mark Foletta
- Experience